3
6
Biemans, V.B.C., Sleutjes, J.A.M., de Vries, A.C., Bodelier, A.G.L., Dijkstra, G., Oldenburg, B., Lowenberg, M., van Bodegraven, A.A., van der Meulen-de Jong, A.E., de Boer, N.K.H., Srivastava, N., West, R.L., Romkens, T.E.H., Horje, C.H.T.S., Jansen, J.M., van der Woude, C.J., Hoekstra, J., Weersma, R.K., van Schaik, F.D.M., Hoentjen, F., Pierik, M.J.
Veröffentlicht in: Biemans , V B C , Sleutjes , J A M , de Vries , A C , Bodelier , A G L , Dijkstra , G , Oldenburg , B , Lowenberg , M , van Bodegraven , A A , van der Meulen-de Jong , A E , de Boer , N K H , Srivastava , N , West , R L , Romkens , T E H , Horje , C H T S , Jansen , J M , van der Woude , C J , Hoekstra , J , Weersma , R K , van Schaik , F D M , Hoentjen , F , Pierik , M J & Dutch Initiative Crohn and Colitis 2020 , ' Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry ' , Alimentary Pharmacology & Therapeutics , vol. 51 , no. 9 , pp. 880-888 . https://doi.org/10.1111/apt.15689;
2020